[HTML] thelancet.com

[HTML][HTML] Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial

JW Eikelboom, SS Jolly, EP Belley-Cote… - The Lancet …, 2022 - thelancet.com
Background COVID-19 disease is accompanied by a dysregulated immune response and
hypercoagulability. The Anti-Coronavirus Therapies (ACT) inpatient trial aimed to evaluate …
被引用次数：22 相关文章

Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial

JW Eikelboom, SS Jolly, EP Belley-Cote… - The Lancet Respiratory …, 2022 - Elsevier
Background COVID-19 disease is accompanied by a dysregulated immune response and
hypercoagulability. The Anti-Coronavirus Therapies (ACT) inpatient trial aimed to evaluate …
[HTML] nih.gov

[HTML][HTML] Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial

JW Eikelboom, SS Jolly, EP Belley-Cote… - The Lancet …, 2022 - ncbi.nlm.nih.gov
Background COVID-19 disease is accompanied by a dysregulated immune response and
hypercoagulability. The Anti-Coronavirus Therapies (ACT) inpatient trial aimed to evaluate …

Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial.

JW Eikelboom, SS Jolly, EP Belley-Cote, RP Whitlock… - 2022 - cabidigitallibrary.org
Background: COVID-19 disease is accompanied by a dysregulated immune response and
hypercoagulability. The Anti-Coronavirus Therapies (ACT) inpatient trial aimed to evaluate …

Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial

JW Eikelboom, SS Jolly, EP Belley-Cote… - The Lancet …, 2022 - scholars.aku.edu
Background: COVID-19 disease is accompanied by a dysregulated immune response and
hypercoagulability. The Anti-Coronavirus Therapies (ACT) inpatient trial aimed to evaluate …

Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial.

JW Eikelboom, SS Jolly, EP Belley-Cote… - The Lancet …, 2022 - europepmc.org
Background COVID-19 disease is accompanied by a dysregulated immune response and
hypercoagulability. The Anti-Coronavirus Therapies (ACT) inpatient trial aimed to evaluate …

Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial

JW Eikelboom, SS Jolly, EP Belley-Cote, RP Whitlock… - 2022 - pubmed.ncbi.nlm.nih.gov
Background COVID-19 disease is accompanied by a dysregulated immune response and
hypercoagulability. The Anti-Coronavirus Therapies (ACT) inpatient trial aimed to evaluate …

Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): An open-label, factorial, randomised, controlled trial

JW Eikelboom, SS Jolly, EP Belley-Cote… - The Lancet …, 2022 - ecommons.aku.edu
Background: COVID-19 disease is accompanied by a dysregulated immune response and
hypercoagulability. The Anti-Coronavirus Therapies (ACT) inpatient trial aimed to evaluate …

Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial.

JW Eikelboom, SS Jolly, EP Belley-Cote… - The Lancet …, 2022 - europepmc.org
COVID-19 disease is accompanied by a dysregulated immune response and
hypercoagulability. The Anti-Coronavirus Therapies (ACT) inpatient trial aimed to evaluate …